Vergelijking

Maridebart Cafraglutide vs. Petrelintide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Maridebart Cafraglutide	Petrelintide
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Maridebart Cafraglutide

Volledige vermelding →

Petrelintide

Volledige vermelding →

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Petrelintide?: Maridebart Cafraglutide is classified as "Metabool", while Petrelintide is classified as "Metabool". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Maridebart Cafraglutide or Petrelintide?: The highest available evidence level is "Humane RCT" for Maridebart Cafraglutide and "Humane RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Maridebart Cafraglutide and Petrelintide in Germany and the United States?: Duitsland: Maridebart Cafraglutide — Niet goedgekeurd, Petrelintide — Niet goedgekeurd. Verenigde Staten: Maridebart Cafraglutide — Niet goedgekeurd, Petrelintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Maridebart Cafraglutide

Petrelintide

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Petrelintide?

Maridebart Cafraglutide is classified as "Metabool", while Petrelintide is classified as "Metabool". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Maridebart Cafraglutide or Petrelintide?

The highest available evidence level is "Humane RCT" for Maridebart Cafraglutide and "Humane RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Maridebart Cafraglutide and Petrelintide in Germany and the United States?

Duitsland: Maridebart Cafraglutide — Niet goedgekeurd, Petrelintide — Niet goedgekeurd. Verenigde Staten: Maridebart Cafraglutide — Niet goedgekeurd, Petrelintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.